Kenneth Harrap

Last updated

Professor
Kenneth Harrap
CBE CChem FRSC
Born
Kenneth Reginald Harrap

(1931-11-20)20 November 1931
Died9 February 2017(2017-02-09) (aged 85)
Nationality United Kingdom
Occupation Oncological biochemist
Employer Institute of Cancer Research

Professor Kenneth Reginald Harrap CBE CChem FRSC (1931-2017) was a British oncological biochemist.

Contents

Early life and education

Harrap was born in Streatham, London, on 20 November 1931. [1] [2] He was educated at Woking Grammar School and George Green's School, London. [2]

He graduated with a BSc in Chemistry from the University of London, then worked for a while as an analytical chemist at Hopkins & Williams. [1]

In 1964 He spent a sabbatical period as a visiting fellow at the Children's Cancer Research Foundation in Boston, United States. [1]

He received a DSc in Pharmacology and Biochemistry from London University in 1977. [3]

Career

The early part of his career was directed at identifying biochemical abnormalities of cancer cells. [4] [5]

In 1956 he moved to the Institute of Cancer Research's Chester Beatty Research Institute in London. [1] [6] He was promoted to Head of the Department of Applied Biochemistry in 1970, Head of the Department of Biochemical Pharmacology in 1977, Chairman of the Drug Development Section in 1982, and Director of the CRC's Centre for Cancer Therapeutics in 1994. [6]

Harrap chaired the British Association for Cancer Research from 1987 to 1990. [1]

He was elected a Fellow of the Royal Society of Chemistry, and received the American Association for Cancer Research's Bruce F. Cain award and the Barnett Rosenberg Award, both in 1995. [1] He was made a Commander of the Order of the British Empire (CBE) in the 1998 New Year Honours, "for services to cancer research". [7]

He is credited with the discovery of Carboplatin, JM 216 (Satraplatin), and AMD 473. [3]

Platinum based anti-cancer agents

A collaboration with Johnson Matthey established by Professor Tom Connors was expanded into an extensive search for an effective but less toxic therapy to replace Cisplatin. [1]

JM8 was identified and successfully launched as Carboplatin (Paraplatin) by Bristol Myers Squibb in 1986. [8] [9] This achievement was recognized in 1991 with the Queens Award for Technological Achievement, awarded jointly to the Drug Development Section at the Institute of Cancer Research, of which Harrap was Head, to the Royal Marsden Hospital, and to Johnson. [10]

Antimetabolite anticancer drugs

Harrap's interest in antimetabolites as cancer drugs led to a collaboration with AstraZeneca on the development of thymidylate synthase inhibitors. Raltitrexed was developed and launched as Tomudex. [11]

Building on the work done by Harrap's group, thymidylate synthase has continued to be a target of interest for the development of anti cancer drugs. One of these, BGC 945, has been taken into clinical trial at the Royal Marsden, and licensed to Carrick for further clinical development. [12]

Retirement

Harrap became emeritus professor of pharmacology at the University of London, a distinguished emeritus fellow of the Cancer Research Campaign, and an associate and visiting scientist at the Institute of Cancer Research on his retirement in 1997. [1] [6] He was profiled as the "Cover Legend" in volume 58, issue 21 (November 1998) of the journal Cancer Research , which featured his portrait photograph on its front page and described him as "one of Britain's top leaders in the field of cancer chemotherapy". [3]

Harrap joined his wife Dr. Beverley Weston to form Weston and Harrap Consulting, advising start up and small biotech companies on cancer drug development and commercial potential. [1]

He died on 9 February 2017. [1] He was survived by his wife, two daughters, and grandchildren. [13] `

The University of London's Harrap Chair of Pharmacology and Therapeutics is endowed in his honour. [13] A blue plaque commemorating the work of the Institute for Cancer Research, including the discovery of Carboplatin, was erected by the Royal Society of Chemistry in 2018. Beverley Weston was one of the speakers at the event. [14]

Related Research Articles

<span class="mw-page-title-main">Gertrude B. Elion</span> American biochemist and pharmacologist (1918–1999)

Gertrude "Trudy"Belle Elion was an American biochemist and pharmacologist, who shared the 1988 Nobel Prize in Physiology or Medicine with George H. Hitchings and Sir James Black for their use of innovative methods of rational drug design for the development of new drugs. This new method focused on understanding the target of the drug rather than simply using trial-and-error. Her work led to the creation of the anti-retroviral drug AZT, which was the first drug widely used against AIDS. Her well known works also include the development of the first immunosuppressive drug, azathioprine, used to fight rejection in organ transplants, and the first successful antiviral drug, acyclovir (ACV), used in the treatment of herpes infection.

The Institute of Cancer Research is a public research institute and a member institution of the University of London in London, United Kingdom, specialising in oncology. It was founded in 1909 as a research department of the Royal Marsden Hospital and joined the University of London in 2003. It has been responsible for a number of breakthrough discoveries, including that the basic cause of cancer is damage to DNA.

<span class="mw-page-title-main">John Vane</span> British scientist

Sir John Robert Vane was a British pharmacologist who was instrumental in the understanding of how aspirin produces pain-relief and anti-inflammatory effects and his work led to new treatments for heart and blood vessel disease and introduction of ACE inhibitors. He was awarded the Nobel Prize in Physiology or Medicine in 1982 along with Sune Bergström and Bengt Samuelsson for "their discoveries concerning prostaglandins and related biologically active substances".

<span class="mw-page-title-main">Thymidine kinase</span> Enzyme found in most living cells

Thymidine kinase is an enzyme, a phosphotransferase : 2'-deoxythymidine kinase, ATP-thymidine 5'-phosphotransferase, EC 2.7.1.21. It can be found in most living cells. It is present in two forms in mammalian cells, TK1 and TK2. Certain viruses also have genetic information for expression of viral thymidine kinases. Thymidine kinase catalyzes the reaction:

<span class="mw-page-title-main">Carboplatin</span> Medication used to treat cancer

Carboplatin, sold under the brand name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.

<span class="mw-page-title-main">Pemetrexed</span> Chemical compound

Pemetrexed, sold under the brand name Alimta among others, is a chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC)..

<span class="mw-page-title-main">Antimetabolite</span> Chemical that inhibits the use of a metabolite

An antimetabolite is a chemical that inhibits the use of a metabolite, which is another chemical that is part of normal metabolism. Such substances are often similar in structure to the metabolite that they interfere with, such as the antifolates that interfere with the use of folic acid; thus, competitive inhibition can occur, and the presence of antimetabolites can have toxic effects on cells, such as halting cell growth and cell division, so these compounds are used in chemotherapy for cancer.

<span class="mw-page-title-main">History of cancer chemotherapy</span>

The era of cancer chemotherapy began in the 1940s with the first use of nitrogen mustards and folic acid antagonist drugs. The targeted therapy revolution has arrived, but many of the principles and limitations of chemotherapy discovered by the early researchers still apply.

Tak Wah Mak, is a Canadian medical researcher, geneticist, oncologist, and biochemist. He first became widely known for his discovery of the T-cell receptor in 1983 and pioneering work in the genetics of immunology. In 1995, Mak published a landmark paper on the discovery of the function of the immune checkpoint protein CTLA-4, thus opening the path for immunotherapy/checkpoint inhibitors as a means of cancer treatment. Mak is also the founder of Agios Pharmaceuticals, whose lead compound, IDHIFA®, was approved by the FDA for acute myeloid leukemia in August 2017, becoming the first drug specifically targeting cancer metabolism to be used for cancer treatment. He has worked in a variety of areas including biochemistry, immunology, and cancer genetics.

<span class="mw-page-title-main">Thromboxane-A synthase</span> Mammalian protein found in Homo sapiens

Thromboxane A synthase 1 , also known as TBXAS1, is a cytochrome P450 enzyme that, in humans, is encoded by the TBXAS1 gene.

<span class="mw-page-title-main">Thymidylate synthase</span> Enzyme

Thymidylate synthase (TS) is an enzyme that catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP). Thymidine is one of the nucleotides in DNA. With inhibition of TS, an imbalance of deoxynucleotides and increased levels of dUMP arise. Both cause DNA damage.

<span class="mw-page-title-main">Paul Workman (scientist)</span> British oncologist (born 1952)

Paul Workman is a British scientist noted for his work on the discovery and development of pharmaceutical agents in the field of oncology. He is President and CEO of The Institute of Cancer Research In London.

Tony Kouzarides, FMedSci, FRS is a senior group leader Gurdon Institute, a founding non-executive director of Abcam and a Professor of Cancer Biology at the University of Cambridge.

<span class="mw-page-title-main">Shankar Balasubramanian</span> Indian-born British chemist

Sir Shankar Balasubramanian is an Indian-born British chemist and Herchel Smith Professor of Medicinal Chemistry in the Department of Chemistry at the University of Cambridge, Senior Group Leader at the Cancer Research UK Cambridge Institute and Fellow of Trinity College, Cambridge. He is recognised for his contributions in the field of nucleic acids. He is scientific founder of Solexa and biomodal.

Craig M. Crews is an American scientist at Yale University known for his contributions to chemical biology. He is known for his contributions to the field of induced proximity through his work in creating heterobifunctional molecules that "hijack" cellular processes by inducing the interaction of two proteins inside a living cell. His initial work focused on the discovery of PROteolysis-TArgeting Chimeras (PROTACs) to trigger degradation of disease-causing proteins, a process known as targeted protein degradation (TPD), and he has since developed new versions of -TACs to leverage other cellular processes and protein families to treat disease.

<span class="mw-page-title-main">Ian A. Graham</span> British biologist (born 1963)

Ian Alexander Graham is a professor of Biochemical Genetics in the Centre for Novel Agricultural Products (CNAP) at the University of York.

<span class="mw-page-title-main">Mark A. Lemmon</span> English biochemist (born 1964)

Mark Andrew Lemmon an English-born biochemist, is the Alfred Gilman Professor and Department Chair of Pharmacology at Yale University where he also directs the Cancer Biology Institute.

<span class="mw-page-title-main">Endoxifen</span> Chemical compound

Endoxifen, also known as 4-hydroxy-N-desmethyltamoxifen, is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group as well as a protein kinase C (PKC) inhibitor. It is under development for the treatment of estrogen receptor-positive breast cancer and for the treatment of mania in bipolar disorder. It is taken by mouth.

<span class="mw-page-title-main">ONX-0801</span> Chemical compound

ONX-0801 is an experimental drug that has been developed to target ovarian cancer. It is a folate receptor alpha mediated thymidylate synthase inhibitor.

<span class="mw-page-title-main">Orlando D. Schärer</span> Swiss chemist and biologist

Orlando David Schärer is a Swiss chemist and biologist researching DNA repair, genomic integrity, and cancer biology. Schärer has taught biology, chemistry and pharmacology at various university levels on three continents. He is a distinguished professor at the Ulsan National Institute of Science and Technology (UNIST) and an associate director of the IBS Center for Genomic Integrity located in Ulsan, South Korea. He leads the three interdisciplinary research teams in the Chemical & Cancer Biology Branch of the center and specifically heads the Cancer Therapeutics Mechanisms Section.

References

  1. 1 2 3 4 5 6 7 8 9 10 "The Drug Discoverer - A pioneer of cancer drug discovery – Professor Ken Harrap 1931–2017 - The Institute of Cancer Research, London". Institute of Cancer Research . Retrieved 26 June 2017.
  2. 1 2 Jackson, Bob; Newell, Herbie (30 March 2017). "Ken Harrap obituary". The Guardian.
  3. 1 2 3 Weinhouse, sydney (November 1998). "Cover Legend" (PDF). Cancer Research (58): [unnumbered front matter page].
  4. ↑ Harrap, K. R. (1965). "Some Aspects of Sulphydryl Metabolism in Granulocytic Leukemia". European Journal of Cancer . 1 (3–4): 189–194. doi:10.1016/0014-2964(65)90047-2. PMID   5226523.
  5. ↑ Harrap, K.R.; Jackson, R.C. (1969). "Some Biochemical Aspects of Leukemias. Leukocyte Glutathione Metabolism in Chronic Granulocytic Leukemias". European Journal of Cancer. 5 (5): 61–67. doi:10.1016/0014-2964(69)90090-5. PMID   5252516.
  6. 1 2 3 Daphne Christie; Tilli Tansey, eds. (2007). The Discovery, Use and Impact of Platinum Salts as Chemotherapy Agents for Cancer. Wellcome Witnesses to Contemporary Medicine. History of Modern Biomedicine Research Group. ISBN   978-0-85484-112-7. OL   25554713M. Wikidata   Q29581749.
  7. ↑ "No. 54993". The London Gazette (Supplement). 30 December 1997. p. 9.
  8. ↑ "Carboplatin: Chemistry for Fighting Cancer". Johnson Matthey.[ dead link ]
  9. ↑ "Scientific Symposium on Paraplatin" (PDF). Platinum metals review. Archived from the original (PDF) on 3 November 2016. Retrieved 12 October 2011.
  10. ↑ "No. 52509". The London Gazette (Supplement). 19 April 1991. p. 4.
  11. ↑ Jackman, Ann L.; Boyle, F. Thomas; Harrap, Kenneth R. (February 1996). "Tomudex TM (ZD1694): from concept to care, a programme in rational drug discovery". Investigational New Drugs. 14 (3): 305–308. doi:10.1007/BF00194534. PMID   8958186.
  12. ↑ Jamala, A. (November 2010). "Antifolate Inhibitors of Thymidylate Synthase as Anticancer Drugs". Mini-Reviews in Medicinal Chemistry . 10 (13): 1211–1222. doi:10.2174/13895575110091211. PMID   20854257.
  13. 1 2 Workman, Paul (15 February 2017). "The Drug Discoverer - A pioneer of cancer drug discovery – Professor Ken Harrap 1931–2017". The Institute of Cancer Research. Retrieved 8 January 2020.
  14. ↑ "Blue Plaque for the Institute for Cancer Research". Royal Society of Chemistry . Retrieved 8 January 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.